• 1
    Michel ML, Deng Q, Mancini-Bourgine M. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges. J Hepatol 2011;54:128696.
  • 2
    Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol 1995;17:26181.
  • 3
    Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990;145:34429.
  • 4
    Chen M, Li YG, Zhang DZ et al. Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study. World J Gastroenterol 2005;11:18068.
  • 5
    Luo J, Li J, Chen RL et al. Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers. Vaccine 2010;28:2497504.
  • 6
    Hepatology of Chinese Medical Association, Chinese Medical Association to infectious diseases. Chronic hepatitis B prevention and treatment guidelines. Liver 2011;16:216.
  • 7
    Chen JM, Wei XM, Chen ZZ. Ex vivo culture of dendritic From peripheral blood cells. Cell Res 2001;23:402.
  • 8
    Xuanyong Lu. Pathogenesis of Hepatitis B Virus (HBV)–Mediated Liver Injury. N A J Med Sci 2011;4:16.
  • 9
    Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010;58:25866.
  • 10
    Min XG. Study of changes in immune response in patients with chronic hepatitis B. J Hosp Infect 2012;22:2802.
  • 11
    Zhang Z, Zhang JY, Wang LF. Immunopathogenesis and prognostic immune markers of chronic hepatitis B virus infection. J Gastroenterol Hepatol 2012;27:22330.
  • 12
    Shimizu Y. Immunopathogenesis and immunotherapy for viral hepatitis. In: Mukololov S, ed. Viral Hepatitis-Selected Issues of Pathogenesis and Diagnosis, Shanghai, China: InTech China, 2011:6582.
  • 13
    Horiike N, Md Fazle Akbar S, Ninomiya T, Abe M, Michitaka K, Onji M. Activation and maturation of antigen-presenting dendritic cells during vaccine therapy in patients with chronic hepatitis due to hepatitis B virus. Hepatol Res 2002;23:3847.
  • 14
    Su HB, Li HW, Zhao HL et al. Therapeutic effect of autologous cytokine-induced killer cells on patients with liver cirrhosis caused by HBV infection. Chin J Exp Clin Virol 2007;21:646.
  • 15
    Märten A, Ziske C, Schöttker B et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. J Immunother 2001;24:50210.
  • 16
    van der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004;40:73846.
  • 17
    Ma Y-J, Han J-A, Yang L, Wang Z-L, Han L, Wang Y-J. Immune effector differences of dendritic cells after HBsAg activation in healthy subjects and Chronic HBV infected patients. World J Gastroenterol 2012;20:3415.
  • 18
    Shi M, Fu J, Shi F et al. Transfusion of autologous cytokine-induced killer cells inhibits viral replication in patients with chronic hepatitis B virus infection. Clin Immunol 2009;132:4354.